News - Gastro-intestinals, naloxegol

Filter

Popular Filters

US FDA accepts AstraZeneca’s NDA for naloxegol

US FDA accepts AstraZeneca’s NDA for naloxegol

19-11-2013

The US Food and Drug Administration has accepted the New Drug Application for naloxegol, an investigational…

AstraZenecaGastro-intestinalsnaloxegolNektar TherapeuticsNorth AmericaPharmaceuticalRegulation

AstraZeneca reveals new safety data for naloxegol in OIC

AstraZeneca reveals new safety data for naloxegol in OIC

15-10-2013

AstraZeneca has released results of a Phase III long-term safety and tolerability study of the once-daily…

AstraZenecaGastro-intestinalsnaloxegolNeurologicalPharmaceuticalResearch

Opioid-induced constipation market expected to see rapid growth by 2017

Opioid-induced constipation market expected to see rapid growth by 2017

13-10-2013

The global market for opioid-induced constipation will increase significantly from $144.42 million in…

AstraZenecabevenopranCubist PharmaceuticalsEuropeGastro-intestinalsMarkets & MarketingnaloxegolNorth AmericaPharmaceuticalRelistorSalix Pharmaceuticals

AstraZeneca’s naloxegol marketing application accepted by EMA

AstraZeneca’s naloxegol marketing application accepted by EMA

27-09-2013

The European Medicines Agency has accepted AstraZeneca’s Marketing Authorization Application for naloxegol…

AstraZenecaEuropeGastro-intestinalsMarkets & MarketingnaloxegolNektar TherapeuticsPharmaceuticalRegulation

Nektar hedges bets on deal with AstraZeneca

12-08-2013

Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

22-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

Encouraging results for AstraZeneca's naloxegol in OIC

26-02-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has announced high-level results from KODIAC-08, an open-label,…

AstraZenecaGastro-intestinalsnaloxegolNeurologicalPharmaceuticalResearch

Back to top